|
Gender
|
|
Male
|
90 (82.6)
|
19 (17.4)
|
109 (100)
|
|
Female
|
140 (92.7)
|
11 (7.3)
|
151 (100)
|
|
Age (years) at 36 months median time of HAART follow up
|
|
< 39
|
122 (86.5)
|
19 (13.5)
|
141 (100)
|
|
> 39
|
108 (90.8)
|
11 (9.2)
|
119 (100)
|
|
Educational level
|
|
No education
|
54 (85.7)
|
9 (14.3)
|
63 (100)
|
|
Primary
|
66 (83.5)
|
13 (16.5)
|
79 (100)
|
|
Secondary and above
|
110 (93.2)
|
8 (6.8)
|
118 (100)
|
|
Residence
|
|
Rural
|
41 (83.7)
|
8 (16.3)
|
49 (100)
|
|
Urban
|
189 (89.6)
|
22 (10.4)
|
211 (100)
|
|
Chronic non-communicable diseasesa
|
|
Yes
|
9 (75.0)
|
3 (25.0)
|
12 (100)
|
|
No
|
221 (89.1)
|
27 (10.9)
|
248 (100)
|
|
INH Prophylaxis given
|
|
Yes
|
119 (93.0)
|
9 (7.0)
|
128 (100)
|
|
No
|
111 (84.1)
|
21 (15.9)
|
132 (100)
|
|
History of TB co-infection
|
|
Yes
|
37 (86.0)
|
6 (14.0)
|
43 (100)
|
|
No
|
193 (88.9)
|
24 (11.1)
|
217 (100)
|
|
History of opportunistic infections (other than TB)b
|
|
Yes
|
126 (88.1)
|
17 (11.9)
|
143 (100)
|
|
No
|
104 (88.9)
|
13 (11.1)
|
117 (100)
|
|
Adherence to treatment
|
|
Fair/Poor
|
9 (50.0)
|
9 (50.0)
|
18 (100)
|
|
Good
|
221 (91.3)
|
21 (8.7)
|
242 (100)
|
|
Regimen given
|
|
TDF basedc
|
179 (90.9)
|
18 (9.1)
|
197 (100)
|
|
AZT basedd
|
49 (81.7)
|
11 (18.3)
|
60 (100)
|
|
ABC basede
|
2 (66.7)
|
1 (33.3)
|
3 (100)
|
|
Age (years) at HAART initiation
|
|
< 35
|
113 (85.6)
|
19 (14.4)
|
132 (100)
|
|
> 35
|
117 (91.4)
|
11 (8.6)
|
128 (100)
|
|
WHO clinical stage at baseline
|
|
I/II
|
112 (91.1)
|
12 (8.9)
|
124 (100)
|
|
III/IV
|
118 (86.8)
|
18 (13.2)
|
136 (100)
|
|
History of malnutrition
|
|
Yes
|
68 (81.9)
|
15 (18.1)
|
83 (100)
|
|
No
|
162 (91.5)
|
15 (8.5)
|
177 (100)
|
|
Cotrimoxazole prophylaxis given (months) (N = 239)
|
|
< 30
|
96 (83.5)
|
19 (16.5)
|
115 (100)
|
|
> 30
|
113 (91.1)
|
11 (8.9)
|
124 (100)
|
|
Viral load (copies/mL) at 36 months median time of HAART follow up
|
|
< 1000
|
221 (96.1)
|
9 (3.9)
|
230 (100)
|
|
> 1000
|
9 (30.0)
|
21 (70.0)
|
30 (100)
|
|
CD4+ count (cells/μl) at baseline
|
|
< 100
|
67 (87.0)
|
10 (13.0)
|
77 (100)
|
|
101–200
|
69 (85.2)
|
12 (14.8)
|
81 (100)
|
|
201–300
|
49 (92.5)
|
4 (7.5)
|
53 (100)
|
|
> 300
|
45 (91.8)
|
4 (8.2)
|
49 (100)
|
|
CD4+ count (cells/μl) at 36 months median time of HAART follow up
|
|
< 100
|
9 (56.2)
|
7 (43.8)
|
16 (100)
|
|
101–200
|
27 (79.4)
|
7 (20.6)
|
34 (100)
|
|
201–300
|
34 (81.0)
|
8 (19.0)
|
42 (100)
|
|
> 300
|
160 (95.2)
|
8 (4.8)
|
168 (100)
|
|
Time interval from HIV Diagnosis to HAART initiation (months)
|
|
< 12
|
175 (87.1)
|
26 (12.9)
|
201 (100)
|
|
> 12
|
55 (93.2)
|
4 (6.8)
|
59 (100)
|
|
HBV co- infection(n = 139)
|
|
Yes
|
7 (63.6)
|
4 (36.4)
|
11 (100)
|
|
No
|
114 (89.1)
|
14 (10.9)
|
128 (100)
|
|
HCV co-infection(n = 64)
|
|
Yes
|
0 (0.0)
|
2 (100)
|
2 (100)
|
|
No
|
53 (85.5)
|
9 (14.5)
|
62 (100)
|
